Засновані на доказах рекомендації 2014 року з лікування високого артеріального тиску в дорослих осіб

A. James Paul, Oparil Suzanne, L. Carter Barry, ... и др

Abstract


Артеріальна гіпертензія (АГ) є найбільш поширеним захворюванням у практиці первинної ланки медичної допомоги й призводить до розвитку інфаркту міокарда, інсульту, ниркової недостатності, а також смерті за умов несвоєчасного виявлення та при відсутності належного лікування. Пацієнти хочуть бути впевненими, що лікувальні заходи з корекції високого артеріального тиску (АТ) приведуть до зменшення тягаря їхньої хвороби, у той час як клініцисти прагнуть мати рекомендації з лікування АГ, при створенні яких були б використані найбільш достовірні наукові дані. Для розробки рекомендацій щодо терапевтичних порогових значень, цілей терапії і стандартів застосування лікарських засобів при лікуванні АГ в осіб дорослого віку в даному звіті було застосовано ретельний підхід, обґрунтований доказами. Доказові дані були отримані з рандомізованих контрольованих клінічних досліджень, що являють собою золотий стандарт у визначенні ефективності та результативності лікування. Якість доказових даних і рекомендації були класифіковані залежно від їх впливу на важливі кінцеві результати (ускладнення. — Прим. ред.).

References


Staessen J.A., Fagard R., Thijs L., et al.; The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension // Lancet. 1997; 350 (9080): 757-764.

Beckett N.S., Peters R., Fletcher A.E., et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. 2008; 358 (18): 1887-1898.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drugt reatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) // JAMA. 1991; 265 (24): 3255-3264.

Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011. http://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx. Accessed November 4, 2013.

Hsu C.C., Sandford B.A. The Delphi technique: making sense of consensus // Pract. Assess. Res Eval. 2007;12 (10). http://pareonline.net/pdf/v12n10.pdf. Accessed October 28, 2013.

Institute of Medicine. Finding What Worksin Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011. http://www.iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-systematic-Reviews.aspx. Accessed November 6, 2013.

Cushman W.C., Evans G.W., Byington R.P., et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. 2010; 362 (17): 1575-1585.

Benavente O.R., Coffey C.S., Conwit R., et al.; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial // Lancet. 2013; 382 (9891): 507-515.

JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) // Hypertens. Res. 2008; 31 (12): 2115-2127.

Ogihara T., Saruta T., Rakugi H., et al.; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study // Hypertension. 2010; 56 (2): 196-202.

Verdecchia P., Staessen J.A., Angeli F., et al.; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial // Lancet. 2009; 374 (9689): 525-533.

Chobanian A.V., Bakris G.L., Black H.R., et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report // JAMA. 2003; 289 (19): 2560-2572.

Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, I: reduction in mortality of persons with high blood pressure, including mild hypertension // JAMA. 1979; 242 (23): 2562-2571.

Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, III: reduction in stroke incidence among persons with high blood pressure // JAMA. 1982; 247 (5): 633-638.

Hypertension — Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence // JAMA. 1974; 229 (4): 409-418.

Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results // Br. Med. J. (Clin. Res. Ed.). 1985; 291 (6488): 97-104.

Report by the Management Committee. The Australian therapeutic trial in mild hypertension // Lancet. 1980; 1 (8181): 1261-1267.

Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg // JAMA. 1970; 213 (7): 1143-1152.

Hansson L., Zanchetti A., Carruthers S.G., et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial // Lancet. 1998; 351 (9118): 1755-1762.

Ruggenenti P., Perna A., Loriga G., et al.; REIN-2 Study Group.Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial // Lancet. 2005; 365 (9463): 939-946.

Wright J.T. Jr, Bakris G., Greene T., et al.; African American Study of Kidney Disease and Hypertension Stud yGroup. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial // JAMA. 2002; 288 (19): 2421-2431.

Klahr S., Levey A.S., Beck G.J., et al.; Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease // N. Engl. J. Med. 1994; 330 (13): 877-884.

Curb J.D., Pressel S.L., Cutler J.A., et al.; Systolic Hypertension in the Elderly Program Cooperative Research Group.Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension // JAMA. 1996; 276 (23): 1886-1892.

Tuomilehto J., Rastenyte D., Birkenhager W.H., et al.; Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension // N. Engl. J. Med. 1999; 340 (9): 677-684.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38 // BMJ. 1998; 317 (7160): 703-713.

Patel A., Mac Mahon S., Chalmers J., et al.; ADVANCE Collaborative Group.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007; 370 (9590): 829-840.

The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH) // J. Hypertens. 1985; 3 (4): 379-392.

Dahlof B., Devereux R.B., Kjeldsen S.E., et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. 2002; 359 (9311): 995-1003.

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Hypertension. 2003; 42 (3): 239-246.

Yusuf S., Teo K.K., Pogue J., et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. 2008; 358 (15): 1547-1559.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic // JAMA. 2002;

(23): 2981-2997.

Leenen F.H., Nwachuku C.E., Black H.R., et al.; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial // Hypertension. 2006; 48 (3): 374-384.

Wright J.T. Jr, Harris-Haywood S., Pressel S., et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. 2008; 168 (2): 207-217.

Lewis E.J., Hunsicker L.G., Clarke W.R., et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. 2001; 345 (12): 851-860.

Brenner B.M., Cooper M.E., de Zeeuw D., et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. 2001; 345 (12): 861-869.

Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D.; The Colla-borative Study Group.Th eeffect of angiotensin-converting-enzyme inhibition on diabetic nephropathy // N. Engl. J. Med. 1993; 329 (20): 1456-1462.

Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for th emanagement of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. 2013; 34 (28): 2159-2219.

Hypertension without compelling indications: 2013CHEP recommendations. Hypertension Canadawebsite.http://www.hypertension.ca/hypertension-without-compelling-indications. Accessed October 30, 2013.

American Diabetes Association. Standards of medical care in diabetes — 2013. Diabetes Care. 2013; 36 (suppl. 1): S11-S66.

Kidney Disease; Improving Globa lOutcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease // Kidney Int. Suppl. 2012; 2 (5): 337-414.

National Institute for Health and Clinical Excellence. Hypertension (CG127). http://www.nice.org.uk/guidance/cg127. Accessed October 30, 2013.

Flack J.M., Sica D.A., Bakris G., et al.; International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement // Hypertension. 2010; 56 (5): 780-800.

Gibbons G.H., Harold J.G., Jessup M., Robertson R.M.,

Oetgen W.J. The next steps in developing clinical practice guidelines for prevention // J. Am. Coll. Cardiol. 2013; 62 (15): 1399-1400.

Gibbons G.H., Shurin S.B., Mensah G.A., Lauer M.S. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute // Circulation. 2013; 128 (15): 1713-1715.

Eckel R.H., Jakicic J.M., Ard J.D., et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology / American Heart Association task force on practice guidelines // Circulation. 2013. doi:10.1161/01.cir.0000437740.48606.d1.




DOI: https://doi.org/10.22141/2224-1485.1.33.2014.82682

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта